Australia's most trusted
source of pharma news
Posted 16 April 2026 AM
Sydney-based Immutep has received some much-welcome good news from the FDA, offering hope to its lead candidate after some "bad juju" around the release of trial results smashed the company's value.
The US regulator has granted Orphan Drug Designation to eftilagimod alfa (efti) for the treatment of soft tissue sarcoma. The decision was supported by clinical data from the Phase 2 EFTISARC-NEO, which trialled efti in combination with MSD's Keytruda in the neoadjuvant setting in patients with resectable soft tissue sarcoma.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.